C-VGB3

C-VGB3 is a selective vascular endothelial growth factor receptor 2 (VEGFR2) antagonist, which inhibits VEGFR2-mediated PI3K/AKT/mTOR and PLCγ/ERK1/2 signaling pathways. C-VGB3 binds to the extracellular domain of VEGFR2, blocking ligand-receptor interaction and inducing apoptosis in endothelial and tumor cells through both intrinsic (involving Bcl2 family and caspases) and extrinsic (death receptor-mediated) pathways. C-VGB3 is promising for research of angiogenesis-related cancers, such as breast cancer[1][2].

Product Specifications

UNSPSC

12352209

Target

Akt; Apoptosis; ERK; mTOR; PI3K; VEGFR

Related Pathways

Apoptosis; MAPK/ERK Pathway; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Cardiovascular Disease

Smiles

O=C(N[C@@H](CSSC[C@@H](C(O)=O)NC1=O)C(N[C@@H](CCCNC(N)=N)C(N2[C@@H](CCC2)C(N3[C@@H](CCC3)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(O)=O)C(NCC(N[C@H]1CC(C)C)=O)=O)=O)=O)=O)=O)=O)[C@H](CCC(O)=O)N

Molecular Formula

C43H67N13O17S2

Molecular Weight

1102.20

References & Citations

[1]Namjoo M, et al. A VEGFB-Based Peptidomimetic Inhibits VEGFR2-Mediated PI3K/Akt/mTOR and PLCγ/ERK Signaling and Elicits Apoptotic, Antiangiogenic, and Antitumor Activities. Pharmaceuticals (Basel) . 2023 Jun 20;16 (6) :906.|[2]Sadremomtaz A, et al. Molecular docking, synthesis and biological evaluation of Vascular Endothelial Growth Factor (VEGF) B based peptide as antiangiogenic agent targeting the second domain of the Vascular Endothelial Growth Factor Receptor 1 (VEGFR1D2) for anticancer application. Signal Transduct Target Ther. 2020 Jun 5;5 (1) :76.